Gestagens in the therapy of endometriosis

1. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017; 107(3): 535-6.

2. American College of Obstetricians and Gynecologists. Practice Bulletin no. 114. Management of endometriosis. Obstet. Gynecol. 2010; 116(1): 223-36.

3. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil. Steril. 2014; 101(4): 927-35.

4. Dunselman G.A., Vermeulen N., Becker C., Calhaz-Jorge C., D’Hooghe T., De Bie B. et al.; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014; 29(3): 400-12.

5. Leyland N., Casper R., Laberge P., Singh S.S. SOGC. Endometriosis: diagnosis and management. J. Obstet. Gynaecol. Can. 2010; 34(Suppl. 2): S1-34.

6. Vercellini P., Buggio L., Berlanda N., Barbara G., Somigliana E., Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil. Steril. 2016; 106(7): 1552-71. e2.

7. Harada T., Momoeda M., Taketani Y., Hoshiai H., Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil. Steril. 2008;90(5): 1583-8.

8. Jenkins T.R., Liu C.Y., White J. Does response to hormonal therapy predict presence or absence of endometriosis? J. Minim. Invasive Gynecol. 2008;15(1): 82-6.

9. Bernuit D., Ebert A.D., Halis G., Strothmann A., Gerlinger C., Geppert K. et al. Female perspectives on endometriosis: findings from the uterine bleeding and pain women’s research study. J. Endometriosis Pelvic Pain Dis. 2011; 3(2): 59-123.

10. Bulun S.E., Cheng Y.H., Pavone M.E., Xue Q., Attar E., Trukhacheva E. et al. Estrogen receptor-b, estrogen receptor-a, and progesterone resistance in endometriosis. Semin. Reprod. Med. 2010; 28(1): 36-43.

11. Bulun S.E., Cheng Y.H., Pavone M.E., Yin P., Imir G., Utsunomiya H. et al. 17b-Hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. Semin. Reprod. Med. 2010; 28(1): 44-50.

12. Schultz J.R., Petz L.N., Nardulli A.M. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J. Biol. Chem. 2005; 280(1): 347-54.

13. Cheng Y.H., Yin P., Xue Q., Yilmaz B., Dawson M.I., Bulun S.E. Retinoic acid (RA) regulates 17b-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism. J. Clin. Endocrinol. Metab. 2008;93(5): 1915-23.

14. Brion F., Le Page Y., Piccini B., Cardoso O., Tong S.K., Chung B.C., Kah O. Screening estrogenic activities of chemicals or mixtures in vivo using transgenic (cyp19a1b-GFP) zebrafish embryos. PLoS One. 2012; 7(5): e36069.

15. Vercellini P., Eskenazi B., Consonni D., Somigliana E., Parazzini F., Abbiati A., Fedele L. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum. Reprod. Update. 2011; 17(2): 159-70.

16. Chapron C., Souza C., Borghese B., Lafay-Pillet M.C., Santulli P., Bijaoui G. et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum. Reprod. 2011; 26(8): 2028-35.

17. Black A., Guilbert E., Costescu D., Dunn S., Fisher W., Kives S. et al. Canadian contraception consensus (part 2 of 4). J. Obstet. Gynaecol. Can. 2015; 37(11): 1035-9.

18. Talukdar N., Bentov Y., Chang P.T., Esfandiari N., Nazemian Z., Casper R.F. Effect of long-term combined oral contraceptive pill use on endometrial thickness. Obstet. Gynecol. 2012; 120(2, Pt 1): 348-54.

19. Seifert-Klauss V., Schmidmayr M., Hobmaier E., Wimmer T. Progesterone and bone: a closer link than previously realized. Climacteric. 2012; 15(Suppl. 1): 26-31.

20. Seo J.W., Lee D.Y., Yoon B.K., Choi D. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 212: 9-12.

21. Strowitzki Т., Faustmann Т., Gerlinger С., Schumacher U., Ahlers C., Seitz C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int. J. Womens Health. 2015; 7: 393-401.

22. Kim S.A., Um M.J., Kim H.K., Kim S.J., Moon S.J., Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci. 2016; 59(6): 506-511.

23. Nenicu A., Körbel C., Gu Y., Menger M.D., Laschke M.W. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator- activated receptor-g by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Hum. Reprod. 2014; 29(5): 1011-24.

24. Monckedieck V., Sannecke C., Husen B., Kumbartski M., Kimmig R., Totsch M. et al. Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model. Mol. Hum. Reprod. 2009; 15(10): 635-43.

25. Liang B., Wu L., Xu H., Cheung C.W., Fung W.Y., Wong S.W., Wang C.C. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reprod. Biol. Endocrinol. 2018; 16(1): 32. https://doi.org/10.1186/s12958-018-0347-9

26. Дубровина С.О., Берлим Ю.Д., Гимбут В.С., Красильникова Л.В., Арешян К.А., Мячина Ю.М., Воронова О.В. Прогнозирование рецидива эндометриоидных кист яичников. Фарматека. 2017; 12: 51-5. [Dubrovina S.O., Berlim Y.D., Gimbut V.S., Krasilnikova L.V., Areeshyan K.A., Myachina Yu.M., Voronova O.V. Prognosis of recurrence of endometrioid cysts of the ovaries. Farmateka. 2017; 12: 51-5. (in Russian)]

27. Адамян Л.В., ред. Эндометриоз: диагностика, лечение и реабилитация. Федеральные клинические рекомендации по ведению больных. М.: Российское общество акушеров-гинекологов; 2013. [Adamyan L.V., ed. Endometriosis: diagnosis, treatment and rehabilitation. Federal clinical guidelines for managing patients. Moscow: Russian Society of Obstetricians and Gynecologists; 2013. (in Russian)]

28. Приказ Минздрава России от 01.11.2012 N 572н (ред. от 12.01.2016) „Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)» (Зарегистрировано в Минюсте России 02.04.2013 N 27960) [Order of the Ministry of Health of Russia from 01.11.2012 N 572n (Edited from 12.01.2016) “On approval of the order of rendering medical aid on the profile of obstetrics and gynecology (except for the use of assisted reproductive technologies)” (Registered in the Ministry of Justice of Russia on 02/04/2013 N 27960) (in Russian)]

29. Schweppe K.W. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009; 65(Suppl. 1): S23-7.

30. Trivedi P., Selvaraj K., Mahapatra P.D., Srivastava S., Malik S. Effective post-laparoscopic treatment of endometriosis with dydrogesterone. Gynecol. Endocrinol, 2007; 23(Suppl. 1): S73-6.

31. Podzolkova N., Tatarchuk T., Doshchanova A., Eshimbetova G., Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol. Endocrinol. 2016; 34(3): 246-9.

32. Schindler A.E. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009; 65(Suppl. 1): S3-11.

33. Trivedi N., Chauhan N., Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol. Endocrinol. 2016; 32(8): 667-71.

Received 12.04.2018

Accepted 28.04.2018